ERNA Key Statistics, Chart & Performance
The current stock price of ERNA is 1.3 USD. In the past month the price decreased by -12.16%. In the past year, price decreased by -79.47%.
ERNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.28 | 388.89B | ||
| AMGN | AMGEN INC | 14.89 | 175.30B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.53 | 116.86B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 80.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 727.27 | 49.00B | ||
| INSM | INSMED INC | N/A | 35.77B | ||
| NTRA | NATERA INC | N/A | 32.49B | ||
| BIIB | BIOGEN INC | 11.09 | 27.23B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.65B | ||
| INCY | INCYTE CORP | 16.56 | 20.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.28 | 20.77B |
Related stock screener links
About ERNA
Company Profile
Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Company Info
ERNEXA THERAPEUTICS INC
1035 Cambridge Street, Suite 18A
Cambridge MASSACHUSETTS US
Employees: 6
Phone: 16177986700
ERNEXA THERAPEUTICS INC / ERNA FAQ
Can you describe the business of ERNEXA THERAPEUTICS INC?
Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
What is the current price of ERNA stock?
The current stock price of ERNA is 1.3 USD. The price decreased by -0.76% in the last trading session.
Does ERNEXA THERAPEUTICS INC pay dividends?
ERNA does not pay a dividend.
How is the ChartMill rating for ERNEXA THERAPEUTICS INC?
ERNA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does ERNEXA THERAPEUTICS INC belong to?
ERNEXA THERAPEUTICS INC (ERNA) operates in the Health Care sector and the Biotechnology industry.
ERNA Technical Analysis
ERNA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ERNA. ERNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ERNA Financial Highlights
Over the last trailing twelve months ERNA reported a non-GAAP Earnings per Share(EPS) of -5.32. The EPS increased by 95.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -297.41% | ||
| ROE | -514.17% | ||
| Debt/Equity | 0 |